I-Mab Added to FTSE Russell Global Equity Index Series

PR Newswire

SHANGHAI and GAITHERSBURG, Md., Sept. 2, 2021 /PRNewswire/ — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE Global Equity Index Series (“GEIS”), following FTSE’s most recent semi-annual review. These inclusions will become effective after the market close on Friday, September 17, 2021:   

  • FTSE Global Mid Cap Index
  • FTSE All-World Index
  • FTSE Global All Cap Index
  • FTSE Global Total Cap Index

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. FTSE GEIS provides a robust global equity index framework. The series includes over 16,000 large, mid, small, and micro cap securities across 49 developed and emerging markets globally, with a wide range of modular indexes available to target specific markets and market segments. For more information, please refer to the Index page on FTSE’s website at https://www.ftserussell.com/products/indices/geisac.

“The FTSE indices are one of the most visible and well-tracked index families in the world. Being included in this marquee equity index series is a tremendous honor and validation of the inspiring journey I-Mab has travelled since its IPO in January 2020,” commented Mr. Jielun Zhu, Director and Chief Financial Officer of I-Mab. “This significant capital market milestone marks the third flagship equity index series I-Mab has been added to, following its inclusion in the NASDAQ Biotech Index in December 2020 and the MSCI China All Shares Index in May 2021. Our recent interim corporate updates have demonstrated that we are not only making rapid progress advancing our deep and highly innovative pipeline globally, but are also well on our way to grow into a fully integrated biopharma company in the next few years. We are extremely excited to share the fruits of our future success with our shareholders.”

About I-Mab

I-Mab (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company’s mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab’s globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company’s unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter and WeChat.

Forward Looking Statements

This press release includes certain disclosures which contain “forward-looking statements.” You can identify forward-looking statements because they contain words such as “anticipate” and “expected.” Forward-looking statements are based on I-Mab’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in filings with the U.S. Securities and Exchange Commission. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

I-Mab Contacts

Jielun Zhu
Chief Financial Officer


[email protected]

+86 21 6057 8000

 

Gigi Feng
Chief Communications Officer


[email protected]

+86 21 6057 5709

 

Investor Inquiries


The Piacente Group, Inc.

Emilie Wu

E-mail: [email protected]

Office line: +86 21 6039 8363

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-added-to-ftse-russell-global-equity-index-series-301368395.html

SOURCE I-Mab

CBAK Energy to Participate at Upcoming JPMorgan China EV Battery Supply Chain Forum

PR Newswire

DALIAN, China, Sept. 2, 2021 /PRNewswire/ — CBAK Energy Technology, Inc. (NASDAQ: CBAT) (“CBAK Energy”, or the “Company”), a leading lithium-ion battery manufacturer and electric energy solution provider, today announced its participation in the following virtual investor conference – JPMorgan China EV Battery Supply Chain Forum (“JPMorgan Forum” or the “Conference”).

On Thursday, September 9, 2021 at 9:00 PM U.S. Eastern Time (On Friday, September 10, 2021 at 9:00 AM Beijing/Hong Kong Time), CBAK Energy management will host a fireside chat at the JPMorgan Forum. Management will be available for one-on-one meetings with institutional investors at the Conference. Portfolio managers and analysts who wish to request a meeting should contact their institutional sales representative at each sponsoring bank.

About CBAK Energy

CBAK Energy Technology, Inc. (NASDAQ: CBAT) is a leading high-tech enterprise in China engaged in the development, manufacturing, and sales of new energy high power lithium batteries. The applications of the Company’s products and solutions include electric vehicles, light electric vehicles, electric tools, energy storage, uninterruptible power supply (UPS), and other high-power applications. In January 2006, CBAK Energy became the first lithium battery manufacturer in China listed on the Nasdaq Stock Market. CBAK Energy has multiple operating subsidiaries in Dalian and Nanjing, as well as a large-scale R&D and production base in Dalian.

For more information, please visit www.cbak.com.cn.

Safe Harbor Statement

This press release contains forward-looking statements, which are subject to change. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All “forward-looking statements” relating to the business of CBAK Energy Technology, Inc. and its subsidiary companies, which can be identified by the use of forward-looking terminology such as “believes”, “expects” or similar expressions, involve known and unknown risks and uncertainties which could cause actual results to differ materially. These factors include but are not limited to: the ability of the Company to meet its contract or agreement obligations; the uncertain market for the Company’s lithium battery cells; business, macroeconomic, technological, regulatory, or other factors affecting the profitability of battery cells designed for energy storage; and risks related to CBAK Energy’s business and risks related to operating in China. Please refer to CBAK Energy’s most recent Annual Report on Form 10-K, as well as other SEC reports that have been filed since the date of such annual report, for specific details on risk factors. Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. CBAK Energy’s actual results could differ materially from those contained in the forward-looking statements. CBAK Energy undertakes no obligation to revise or update its forward-looking statements in order to reflect events or circumstances that may arise after the date of this release unless expressly requested by applicable law.

For investor and media inquiries, please contact:

In China:

CBAK Energy Technology, Inc.
Investor Relations Department
Phone: 86-411-39185985
Email: [email protected]

The Blueshirt Group
Ms. Feifei Shen
Phone: +86 13466566136
Email: [email protected]

In the United States:

The Blueshirt Group
Ms. Julia Qian
Phone: +1 973-619-3227
Email: [email protected]

Cision View original content:https://www.prnewswire.com/news-releases/cbak-energy-to-participate-at-upcoming-jpmorgan-china-ev-battery-supply-chain-forum-301368043.html

SOURCE CBAK Energy Technology, Inc.

Acurx Pharmaceuticals to Join the Russell Microcap Index®

PR Newswire

STATEN ISLAND, N.Y., Sept. 2, 2021 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company is set to join the Russell Microcap® Index when the market opens on September 20, 2021, according to a preliminary list of additions posted on September 1, 2021.  

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

“Inclusion in the Russell Microcap Index reflects the ongoing achievement of our previously stated drug development objectives for our pipeline of DNA polymerase IIIC inhibitors, and the fact that, if approved, we would bring to market the first of a new class of antibiotics in over 30 years,” said David P. Luci, President and CEO of Acurx. “Inclusion in the Index benefits our Company and stockholders by elevating our visibility within the global investment community. We look forward to continuing our progress towards completing the clinical development program for ibezapolstat, our lead antibiotic candidate targeting the treatment of C. difficile Infection and delivering on several key milestone catalysts through 2021 and 2022,” concluded Luci.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

About FTSE Russell

FTSE Russell is a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products, and index-based derivatives.  A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles.

FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information on the Russell Microcap® Index and the Russell indexes reconstitution, please visit www.ftserussell.com.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company’s approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcusaureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).  To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other factors. In addition, the forward-looking statements included in this press release represent our views as of August 30, 2021.   We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward- looking statements at some point in the future, we specifically disclaim any obligation to do so.

Investor Contact:

Acurx Pharmaceuticals, Inc.
David P. Luci, President & CEO
Tel:  917-533-1469
Email:  [email protected]

Cision View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-join-the-russell-microcap-index-301368326.html

SOURCE Acurx Pharmaceuticals, Inc.

DICK’S Sporting Goods Announces Participation in the Goldman Sachs 28th Annual Global Retailing Virtual Conference

PR Newswire

PITTSBURGH, Sept. 2, 2021 /PRNewswire/ — DICK’S Sporting Goods, Inc. (NYSE: DKS) today announced that management will present at the Goldman Sachs 28th Annual Global Retailing Virtual Conference on Thursday, September 9th at 9:10 a.m. Eastern Time.

The presentation will be webcast and can be accessed live or as an archived replay from the link on the DICK’S Sporting Goods’ Investor Relations website at investors.DICKS.com.


About DICK’S Sporting Goods, Inc.

Founded in 1948, DICK’S Sporting Goods is a leading omni-channel sporting goods retailer offering an extensive assortment of authentic, high-quality sports equipment, apparel, footwear and accessories. As of July 31, 2021, the Company operated 731 DICK’S Sporting Goods locations across the United States, serving and inspiring athletes and outdoor enthusiasts to achieve their personal best through a combination of its dedicated teammates, in-store services and unique specialty shop-in-shops dedicated to Team Sports, Athletic Apparel, Golf, Outdoor, Fitness and Footwear.

Headquartered in Pittsburgh, DICK’S also owns and operates Golf Galaxy and Field & Stream specialty stores, as well as GameChanger, a youth sports mobile app for scheduling, communications, live scorekeeping and video streaming. DICK’S offers its products through a dynamic eCommerce platform that is integrated with its store network and provides athletes with the convenience and expertise of a 24-hour storefront. For more information, visit the Investor Relations page at dicks.com.


Contacts:

Investor Relations:
Nate Gilch, Senior Director of Investor Relations
DICK’S Sporting Goods, Inc.
(724) 273-3400 or [email protected]

Media Relations:
(724) 273-5552 or [email protected]

Category: Financial

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dicks-sporting-goods-announces-participation-in-the-goldman-sachs-28th-annual-global-retailing-virtual-conference-301367844.html

SOURCE DICK’S Sporting Goods, Inc.

Seelos Therapeutics Announces Appointment of Margaret Dalesandro to the Board of Directors

PR Newswire

NEW YORK, Sept. 2, 2021 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the appointment of Margaret Dalesandro, Ph.D. to its Board of Directors. 

Dr. Margaret Dalesandro is an accomplished biopharmaceutical executive with over 30 years of experience in drug development and commercialization. She held senior executive leadership positions at ImClone Systems, Inc. and in her role as Vice President of Project, Portfolio and Alliance Management, she managed the successful development of ERBITUX (cetuximab), which contributed significantly to the $6.5 billion sale of ImClone to Eli Lilly and Company in 2008. Prior to ImClone Systems Inc., Dr. Dalesandro served as an Executive Director of Cardiovascular/Oncology Project/Portfolio/Alliance Management at GlaxoSmithKline plc. Earlier in her career, she was Director of Cardiovascular Research and Assistant Director of Immunobiology Research and Development, Pharmaceutical Division, at Centocor, Inc. where her research contributed to the successful development of REMICADE (Infliximab).

“Margaret brings an enormous amount of drug development and commercialization experience to Seelos,” said Raj Mehra, Ph.D., Chairman and CEO of Seelos. “We expect significant contributions from her as we proceed with late-stage development of several of our assets in the clinic.”

She is the founder and currently president of Brecon Pharma Consulting LLC, a full-service pharmaceutical and biotechnology consultancy focused on identifying and obtaining critical information early in product development.

Dr. Dalesandro holds M.A. and Ph.D. degrees in Biochemistry from Bryn Mawr College and completed an NIH Postdoctoral fellowship in Molecular Immunology at Wake Forest University. Dr. Dalesandro is Chair of the Board of Directors of OncoSec Medical Incorporated and a member of the Board of Directors of Skye Bioscience, Inc.

About Seelos Therapeutics:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company’s robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD),  Amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson’s Disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: https://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Forward Looking Statements

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All information in this press release is as of September 1, 2021 and we undertake no duty to update this information. A more complete description of these risks can be found in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year-ended December 31, 2020 and our Quarterly Report on Form 10-Q for the quarter-ended June 30, 2021.

Contact Information:

Anthony Marciano

Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
[email protected] 
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-appointment-of-margaret-dalesandro-to-the-board-of-directors-301367786.html

SOURCE Seelos Therapeutics, Inc.

Blueprint Medicines to Present at Morgan Stanley 19th Annual Global Healthcare Conference

PR Newswire


CAMBRIDGE, Mass.
, Sept. 2, 2021 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that Kate Haviland, Blueprint Medicines’ Chief Operating Officer, and Fouad Namouni, M.D., Blueprint Medicines’ President, Research & Development, will participate virtually in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 12:30 p.m. ET.

A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines’ website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines’ website for 30 days following the presentation.

About Blueprint Medicines

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-morgan-stanley-19th-annual-global-healthcare-conference-301366780.html

SOURCE Blueprint Medicines Corporation

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in September:

  • Morgan Stanley 19th Annual Global Healthcare Conference: Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, September 9, 2021 at 1:15 p.m. ET. Members of management will also be available for one-on-one meetings.
  • H.C. Wainwright 23rd Annual Global Investment Conference: Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a pre-recorded fireside chat, which will become available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m. ET. Members of management will also be available for one-on-one meetings.

Both presentations will be available on the News and Events section of the company’s website at www.cabalettabio.com. Replays will be available on the website for 90 days.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta’s proprietary technology, utilizes CAAR T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please visit our website (DesCAARTes™ Phase 1 Trial). The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.

Contacts:

Anup Marda
Chief Financial Officer
[email protected]

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected]



Boxed to Participate in September Investor Conferences

NEW YORK, Sept. 02, 2021 (GLOBE NEWSWIRE) — Boxed (“Boxed” or “the Company”), an e-commerce grocery platform selling bulk consumables to households and businesses, and an e-commerce enabler selling software and services to enterprise retailers around the world, announced today that Boxed will participate in the following investor conferences in September.

  • Thursday, September 9, 2021 – DA Davidson 20th Annual Software and Internet Conference: The company will be hosting a fireside chat which will begin at 3:00 p.m. ET. The Company will also be participating in one-on-one and small group meetings. The fireside chat will be webcast live and will be available for replay, and will be found on the “Events” section of Boxed’s Investor Relations website at https://www.boxed.com/investors.
  • Tuesday, September 21, 2021 – Citi’s 5

    th

    Annual Consumer Disruptive Growth Conference: The Company will be participating in one-on-one and small group meetings.
  • Thursday, September 23, 2021 – Wells Fargo 4

    th

    Annual Consumer Conference: The Company will be participating in one-on-one and small group meetings.

On June 13, 2021, Boxed and Seven Oaks Acquisition Corp. (“Seven Oaks” or “SVOK”) (Nasdaq: SVOK, SVOKU, SVOKW), a publicly-traded special purpose acquisition company, entered into a definitive agreement relating to the business combination that would result in Boxed becoming a public company upon the closing of the transaction. Boxed also announced its intention to list on the New York Stock Exchange (“NYSE”) upon the closing of the business combination, which is expected in the fourth quarter of 2021. The combined company will be called Boxed, Inc. and its common stock and warrants are expected to list on the NYSE under the new ticker symbols “BOXD” and “BOXD WS”, respectively.

About Boxed

Boxed is an e-commerce retailer and an e-commerce enabler. The Company operates an e-commerce retail service that provides bulk pantry consumables to businesses and household customers, without the requirement of a “big-box” store membership. This service is powered by the Company’s own purpose-built storefront, marketplace, analytics, fulfillment, advertising, and robotics technologies. Boxed further enables e-commerce through its Software & Services business, which offers customers in need of an enterprise-level e-commerce platform access to its end-to-end technology. The Company has developed a powerful, unique brand, known for doing right by its customers, employees and society.

About Seven Oaks Acquisition Corp.

Seven Oaks Acquisition Corp. is a special purpose acquisition company formed for the purpose of entering into a business combination. Its goal is to deliver attractive and sustainable returns to investors through an investment in a growth-oriented company that aspires to make a positive social impact with an emphasis on good Environmental, Social and Governance (“ESG”) practices. Seven Oaks raised $258.75 million in its initial public offering in December 2020 and its securities are listed on Nasdaq under the tickers “SVOK,” “SVOKU” and “SVOKW.” Seven Oaks is led by an experienced team of managers, operators and investors who have played important roles in helping build and grow profitable public and private businesses to create value for stockholders. For more information please visit www.sevenoaksacquisition.com.

Important Information About the Business Combination and Where to Find It

Seven Oaks has filed a registration statement on Form S-4 with the SEC, which includes a proxy statement/prospectus, that will be both the proxy statement to be distributed to Seven Oaks’ stockholders in connection with its solicitation of proxies for the vote by Seven Oaks’ stockholders with respect to the business combination and other matters as may be described in the registration statement, as well as the prospectus, and relating to the offer and sale of the securities to be issued in the business combination to certain of Boxed’s stockholders. After the registration statement is declared effective, Seven Oaks will mail a definitive proxy statement/prospectus and other relevant documents to its stockholders. This press release does not contain all the information that should be considered concerning the proposed business combination and is not intended to form the basis of any investment decision or any other decision in respect of the business combination. Seven Oaks’ stockholders and other interested persons are advised to read the preliminary proxy statement/prospectus included in the registration statement and the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed business combination, as these materials will contain important information about Boxed, Seven Oaks and the business combination.

When available, the definitive proxy statement/prospectus and other relevant materials for the proposed business combination will be mailed to stockholders of Seven Oaks as of a record date to be established for voting on the proposed business combination. Stockholders will also be able to obtain copies of the preliminary proxy statement, the definitive proxy statement and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to Seven Oaks’ secretary at 445 Park Avenue, 17th Floor, New York, NY 10022, (917) 214-6371.

Participants in the Solicitation

Seven Oaks and its directors, executive officers, other members of management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of Seven Oaks’ stockholders in connection with the business combination. Investors and security holders may obtain more detailed information regarding the names and interests in the business combination of Seven Oaks’ directors and officers in Seven Oaks’ filings with the SEC, including the Registration Statement on Form S-4 filed with the SEC by Seven Oaks, which includes the proxy statement/prospectus of Seven Oaks for the business combination. Stockholders can obtain copies of Seven Oaks’ filings with the SEC, without charge, at the SEC’s website at www.sec.gov.

Boxed and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of Seven Oaks in connection with the proposed business combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination will be included in the proxy statement/prospectus for the business combination when available.

Forward-Looking Statements

Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events, such as expected timing for the proposed business combination. For example, statements regarding the satisfaction of closing conditions to the proposed business combination and the timing of the completion of the proposed business combination are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “pro forma”, “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Seven Oaks and its management, and Boxed and its management, as the case may be, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the occurrence of any event, change or other circumstances that could give rise to the termination of subsequent definitive agreements with respect to the proposed business combination; (ii) the outcome of any legal proceedings that may be instituted against Seven Oaks, Boxed, the combined company or others following the announcement of the business combination and any definitive agreements with respect thereto; (iii) the inability to complete the business combination due to the failure to obtain approval of the stockholders of Seven Oaks or Boxed; (iv) the inability of Boxed to satisfy other conditions to closing; (v) changes to the proposed structure of the business combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the business combination; (vi) the ability to meet stock exchange listing standards in connection with and following the consummation of the proposed business combination; (vii) the risk that the proposed business combination disrupts current plans and operations of Boxed as a result of the announcement and consummation of the proposed business combination; (viii) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (ix) costs related to the business combination; (x) changes in applicable laws or regulations; (xi) the possibility that Boxed or the combined company may be adversely affected by other economic, business, regulatory, and/or competitive factors; (xii) Boxed’s estimates of expenses and profitability; (xiii) the evolution of the markets in which Boxed competes; (xiv) the ability of Boxed to implement its strategic initiatives and continue to innovate its existing offerings; (xv) the ability of Boxed to defend its intellectual property; (xvi) the ability of Boxed to satisfy regulatory requirements; (xvii) the impact of the COVID-19 pandemic on Boxed’s and the combined company’s business; and (xviii) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form S-4 referenced above and other documents to be filed with the SEC by Seven Oaks.

Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Neither Seven Oaks nor Boxed undertakes any duty to update these forward-looking statements.

Investor Contacts

Seven Oaks:
Drew Pearson
[email protected]

Boxed:
Chris Mandeville
ICR
[email protected]

Media Contacts

Boxed:
Keil Decker
ICR
[email protected]



Gentherm Invests in Electric Sensor Technology Company Forciot

NORTHVILLE, Mich., Sept. 02, 2021 (GLOBE NEWSWIRE) — Gentherm (NASDAQ: THRM), a global market leader and developer of innovative thermal management technologies, announced that it has invested in Forciot, a Finnish-based technology developer of sensors for touch, motion and force measurement.

The technology being developed by Forciot has the potential to be integrated into vehicle interiors, including into steering wheels for Hands on Detection (HOD) functionality for Advanced Driver Assistance Systems (ADAS). Forciot’s innovative stretchable and printed sensors and advanced electronics are targeted to help accurately measure touch, motion and force. Forciot’s sensors may be used to sense an occupant’s presence and potentially to replace buttons and other Human-Machine Interfaces (HMI) within vehicle interiors.

“The automotive industry is changing extremely fast, and we see potential opportunities with Forciot’s stretchable electronics and sensor technology to address the challenges that our customers are facing today and in the future,” said Phil Eyler, President and CEO of Gentherm. “Our investment in Forciot provides us an opportunity to expand our Automotive and Electronics solutions and help improve vehicle safety and passenger comfort.”

“We are very excited to cooperate with Gentherm, who passionately drives innovation and advanced functionality to their future solutions. This cooperation and investment enables us to scale up Forciot operations further to prepare for the mass volume phase and supports our global business and technology development growth plans as well,” said Tytti Julkunen, Forciot Chairman of the Board.

Gentherm Investor Contact

Yijing Brentano
[email protected] 
248.308.1702

Gentherm Media Contact

Melissa Fischer
[email protected] 
248.289.9702

Forciot Media Contact

Tytti Julkunen
[email protected]
+ 358 504877357

About Gentherm

Gentherm (NASDAQ:THRM) is a global developer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery performance solutions, cable systems and other electronic devices. Medical products include patient temperature management systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Gentherm has more than 11,000 employees in facilities in the United States, Germany, Canada, China, Hungary, Japan, Korea, North Macedonia, Malta, Mexico, United Kingdom, Ukraine, and Vietnam. For more information, go to www.gentherm.com.

About Forciot

Forciot is a fast-paced, award-winning scaleup company established in December 2015. The company drives cutting-edge IoT-sensor solutions to enable customers to transform their products, to sense and interact with the changing world in extraordinary new and sustainable ways to conquer growing markets. Forciot is leading the new era of electronics with its stretchable force sensor technology. The Forciot technology works on and with several surface materials, which means it can be integrated into various products and equipment of different size and shape. In addition, it can be used on both rigid and soft surfaces and unlike many competing solutions, it reacts to and measures a broad variety of parameters such as force, weight, load, balance, pressure, and touch accurately and in real time.

Forciot’s key market focus areas are the automotive and logistics sectors. Additionally, Forciot technology can be used for an incredibly broad variety of purposes in different areas of life, such as consumer electronics, wearables, healthcare, aviation, retail – and much more. For more information, go to http://www.forciot.com.

Forward-Looking Statements 
Except for historical information contained herein, statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Gentherm Incorporated’s goals, beliefs, plans and expectations about its prospects for the future and other future events. The forward-looking statements included in this press release are made as of the date hereof or as of the date specified herein and are based on management’s reasonable expectations and beliefs. Such statements are subject to a number of important assumptions, risks, uncertainties and other factors that may cause actual results or performance to differ materially from that described in or indicated by the forward-looking statements. Those risks include, but are not limited to, risks related to: market acceptance of the Company’s existing or new products, and new or improved competing products developed by competitors with greater resources; shifting customer preferences, including due to the evolving use of automobiles and technology; the electric vehicle market and the alignment of the Company’s product portfolio with long-term technological trends; and the feasibility of Company’s development of new products on a timely, cost effective basis, or at all. The foregoing risks should be read in conjunction with the Company’s filings with the Securities and Exchange Commission (the “SEC”), including “Risk Factors”, in its most recent Annual Report on Form 10-K and subsequent SEC filings, for a discussion of these and other risks and uncertainties. In addition, the business outlook discussed in this press release does not include the potential impact of any business combinations, acquisitions, divestitures, strategic investments and other significant transactions that may be completed after the date hereof, each of which may present material risks to the Company’s future business and financial results. Except as required by law, the Company expressly disclaims any obligation or undertaking to update any forward-looking statements to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.​



Lumos Pharma to Participate in September Investor Conferences

AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference and the Cantor Virtual Global Healthcare Conference in September.

Event: H.C. Wainwright 23

rd

Annual Global Investor Conference – September 13-15
Presentation: Pre-recorded presentation available beginning September 13 at 7:00 AM (ET)
Webcast link: Here
Event: Cantor Virtual Global Healthcare Conference – September 27-30
Presentation: Live fireside chat September 29 from 4:00-4:30 PM (ET)
Webcast link: Here

The webcasts for each presentation can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section where a replay of each presentation will be also be available. Please contact your H.C. Wainwright or Cantor salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conferences or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
[email protected]

Source: Lumos Pharma, Inc.